Exagen Inc. XGN
5.26 USD -1.84 (-25.92%)
At closeNov 10, 2026, 7:49 PM EST
5.50 +0.24 +4.56%
After hours · Nov 10, 7:49 PM ET
4.62 Day range 6.30
2.65 52-week range 9.59
- YTD
- -13.49%
- 1 year
- -44.40%
News
marketbeat.com What Exagen (XGN) Said on Its Q3 Earnings Call Exagen NASDAQ: XGN reported third-quarter revenue of $18.4 million, up 7% from a year earlier, as higher test volume and pricing helped the autoimmune diagnostics company post what management…
seekingalpha.com Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PepGen (NASDAQ:PEPG) stock rose 126.6% to $5.42 during Tuesday's regular session. The company's market cap stands at $165.5 million. The company's, Q3 earnings came out today. Nano X Imaging
zacks.com Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
benzinga.com Exagen Q3 2026 Earnings Call Transcript Exagen (NASDAQ:XGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Exagen Affirms FY2026 Sales Guidance of $72.000M-$75.000M vs $73.886M Est Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $72.000 million-$75.000 million to $72.000 million-$75.000 million vs $73.886 million estimate.- benzinga.com Exagen Q3 EPS $(0.25) Misses $(0.18) Estimate, Sales $18.417M Beat $18.343M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 31.58 percent decrease over losses of $(0.19) per…
globenewswire.com Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) --…
benzinga.com Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.- benzinga.com TD Cowen Maintains Buy on Exagen, Raises Price Target to $11 TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.
- benzinga.com Full Transcript: Exagen Q2 2026 Earnings Call On Tuesday, Exagen (NASDAQ:XGN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive…
benzinga.com B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12 B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
benzinga.com Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.- benzinga.com Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8 Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.
- benzinga.com Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests Alone Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markersDemonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier,…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M Est Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $70.000 million-$73.000 million to $70.000 million-$73.000 million vs $71.267 million estimate.
benzinga.com Exagen Q1 EPS $(0.17) Beats $(0.23) Estimate, Sales $17.306M Beat $16.414M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 15 percent increase over losses of $(0.20) per…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $10 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $15 to $10.
- benzinga.com Craig-Hallum Maintains Buy on Exagen, Lowers Price Target to $10 Craig-Hallum analyst John Wilkin maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $12 to $10.
- benzinga.com Keybanc Maintains Overweight on Exagen, Lowers Price Target to $10 Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $15 to $10.
benzinga.com 4 Analysts Have This To Say About Exagen 
benzinga.com Exagen Earnings Report: Q4 Overview 
benzinga.com Exagen Q4 EPS $(0.20) Misses $(0.18) Estimate, Sales $16.631M Beat $16.567M Estimate. Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is unchanged from the same period last year. The…- benzinga.com Earnings Scheduled For March 10, 2026
benzinga.com A Peek at Exagen's Future Earnings 
benzinga.com TD Cowen Maintains Buy on Exagen, Lowers Price Target to $10 TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $13 to $10.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com B. Riley Securities Reiterates Buy on Exagen, Lowers Price Target to $8 B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $18 to $8.
- benzinga.com B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $18 B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $15 to $18.
- benzinga.com CORRECTION: Exagen Q3 Adj. EPS $(0.19) Misses $(0.16) Estimate, Sales $17.244M Beat $16.895M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 20.25 percent. This is a 32.14 percent increase over losses of $(0.28) per…
- benzinga.com Exagen Affirms FY2025 Sales Guidance of $65.000M-$70.000M vs $67.487M Est Exagen (NASDAQ:XGN) affirms FY2025 sales outlook from $65.000 million-$70.000 million to $65.000 million-$70.000 million vs $67.487 million estimate.
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday 
benzinga.com Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $15 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $11 to $15.- benzinga.com Demystifying Exagen: Insights From 5 Analyst Reviews
- benzinga.com Keybanc Maintains Overweight on Exagen, Raises Price Target to $15 Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $12 to $15.
- benzinga.com Beyond The Numbers: 4 Analysts Discuss Exagen Stock
- benzinga.com B. Riley Securities Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $15 B. Riley Securities analyst Anderson Schock initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $15.
- benzinga.com Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $11.
- benzinga.com What Analysts Are Saying About Exagen Stock
- benzinga.com Keybanc Upgrades Exagen to Overweight, Maintains Price Target to $12 Keybanc analyst Paul Knight upgrades Exagen (NASDAQ:XGN) from Sector Weight to Overweight and maintains the price target from $12 to $12.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Exagen Q2 Adj. EPS $(0.18) Misses $(0.14) Estimate, Sales $17.202M Beat $16.233M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 12.5 percent decrease over losses of $(0.16) per…
- benzinga.com Earnings Scheduled For July 29, 2025
- benzinga.com Craig-Hallum Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $12 Craig-Hallum analyst John Wilkin initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $12.